Society for Neuroscience - Search

Skip Navigation

  • join logo Join
  • hands shaped like a yellow heart icon Give
  • advocate logo Advocate
  • publish logo Publish
  • Icon with thought bubbles Learn
Shop Sign In
SfN Logo 2025
  • Membership
    • Learn About Membership
      • Individual Member Benefits
      • Institutional Program Member Benefits
      • Sustaining Associate Member Benefits
      • Get Involved at SfN
    • Become a Member
      • Sponsorship Information for New Members
      • Membership Categories & Fees
      • Membership Fees for Developing Countries
      • Renew Individual Membership
    • Member Resources
      • Automatic Renewals
      • Frequently Asked Questions
      • Individual Member Directory
      • Member Obituaries and Memorial Donations
    • Learn About Local Chapters
      • Start or Reactivate a Chapter
      • Resources for Chapters
      • Submit Annual Report
      • Chapter Directory
      • Frequently Asked Questions
  • Meetings
    • Meetings Overview
    • Neuroscience 2026
      • Dates and Deadlines
      • Exhibits
      • Housing and Travel
      • Call for Abstracts
      • Sessions and Events
      • Registration
      • Advertising and Sponsorship
      • FAQs
    • Global Events
      • SfN Virtual Events
    • Past and Future Annual Meetings
      • Neuroscience 2025
      • Neuroscience 2024
      • Search Past Annual Meeting Abstracts
      • Attendance Statistics
    • Meeting Policies and Guidelines
      • Code of Conduct at SfN Events
      • Growth and Opportunity Strategy
      • Photography & Recording Policy
      • Presenter Guidelines and Policies for SfN Events
    • Meeting Awards
      • Trainee Professional Development Award
      • International Travel Awards
      • FENS Member Awards to SfN Annual Meeting
      • IBRO Member Awards to SfN Annual Meeting
      • JNS Member Awards to SfN Annual Meeting
  • Careers
    • Careers Overview
    • Institutional Program (IP) Directory
    • NeuroJobs Career Center
      • Job Seekers
      • Employers
    • 2025 Graduate School Fair
    • Career Tools and Resources
      • Neuronline
      • Neurobiology of Disease Workshop
      • Responsible Conduct of Research Short Courses
      • Neuroscience Departments and Program Workshop
      • Global Funding Sources
    • Higher Education and Training
      • Core Competencies
      • Neuroscience Training Program Survey
    • Awards
      • Outstanding Career and Research Achievements
      • Early Career
  • Initiatives
    • Initiatives Overview
    • Awards
      • 2025 Award Recipients
      • Awards and Prizes FAQ
      • Trainee Professional Development Award
    • Neuroscience Scholars Program
    • Neuronline
      • Webinars
      • Articles
      • Videos
      • Podcasts
      • Collections
    • Resources to Stay Connected
      • SfN Zoom Backgrounds
    • Community
    • Women and Neuroscience
      • Increasing Women in Neuroscience (IWiN) Courses & Toolkit
      • Celebration of Women in Neuroscience Event
      • Awards
    • Animals in Research
      • Support for Members and Institutions
      • Tools and Resources
      • Resources for Medical Students
    • Public Education Programs
      • Resources for Educators
      • Brain Awareness Video Contest
      • Life of a Neuron Exhibit
  • Advocacy
    • Advocacy Overview
    • Advocacy Response
    • Advocacy Network
      • The NeuroAdvocate Challenge
      • Advocacy Action Center
      • Advocacy Best Practices
      • Advocacy Network News
      • Advocacy Training Seminars
    • US Advocacy Programs
      • Capitol Hill Day
      • Connect with Policymakers
      • Early Career Policy Ambassadors
      • Partner with a Local Chapter
      • Engage the Media
    • Global Advocacy Programs
      • Global Neuroscience Initiatives
      • Global Funding
      • North American Programs
    • Science Funding
      • Advocacy Videos
      • Advocacy Resources
      • US Neuroscience Initiatives
      • Funding Priorities and Processes
    • Policy Positions
      • Statements and Testimony
      • Sign-On Letters
  • Outreach
    • Outreach Overview
    • BrainFacts.org
    • Find a Neuroscientist
    • Brain Awareness Campaign
      • Webinar: The ABC's of BAW
      • How to Get Involved
    • Awards
      • Award for Education in Neuroscience
      • Next Generation Award
      • Chapter of the Year Award
      • Science Educator Award
  • Publications
    • Publications Overview
    • SfN News
    • JNeurosci
    • eNeuro
    • SfN Nexus
    • Neuroscience Quarterly
    • Annual Report
    • History of Neuroscience Autobiographical Chapters
  • About
    • About Overview
    • Mission and Strategic Plan
    • What We Do
      • Annual Report
      • Bylaws
      • Resolutions to the Bylaws
      • Environmental Commitment
      • Strategic Partners
      • History of SfN
    • SfN 50th Anniversary Celebration
    • NIH Public Health Service-Supported Funding Financial Conflict of Interest Policy
    • Volunteer
      • SfN Council
      • SfN Presidents
      • Committees
      • Elections
      • Call for Nominations
    • Professional Conduct
      • SfN Ethics Policy
      • Guidelines for Responsible Conduct Regarding Scientific Communication
      • Code of Conduct at SfN Events
      • Commitment to Scientific Integrity
      • Neuronline Digital Learning Community Guidelines
    • History of Neuroscience
      • Autobiographical Chapters
      • Autobiographical Videos of Prominent Neuroscientists
      • Classic Papers
      • Neuroscience History Resources
      • Robert Doty's Chapter on Neuroscience
    • Careers and Staff
      • Staff List
  1. Search

Filter

  • (1)
  • (1)
  • (4)
  • (74)
  • (4)
Filter
61 - 70 of 109 results
  • Abstract
    Antiemetic effects of ondansetron and delta-9-tetrahydrocannabinol in Suncus murinus (house MuSK shrew).
    The present study investigated the potential of various doses of delta-9-tetrahydrocannabinol (THC), Ondansetron (5-HT3 receptor antagonist, OND) and a combined pretreatment of OND and THC to suppress cisplatin-induced emesis in the Suncus murinus. OND and THC both dose-dependently suppressed cisplatin-induced vomiting and retching. Furthermore, a combined pretreatment of doses of the two drugs that were ineffective alone (0.02 mg/kg OND and 1.25 mg/kg THC) completely suppressed vomiting and retching. This suggests that a combination of lower doses of these agents may be an effective alternative treatment for vomiting that may have fewer side effects than higher doses of either agent alone.
    Nov 11, 2003
  • Abstract
    THE ENDOGENOUS CANNABINOID 2-ARACHIDONOYLGLYCEROL INDUCES VOMITING: BLOCKADE BY MARIJUANA AND IT'S SYNTHETIC ANALOGS.
    We have recently shown that large doses of the cannabinoid CB1 receptor antagonist/inverse agonist SR 141716A induces emesis which can be reversed by Δ9-THC and synthetic cannabinoids. Furthermore, low nonemetic doses of SR 141716A block the antiemetic effect of Δ9-THC against cisplatin-induced vomiting. These studies implicate a role for endogenous cannabinoids in emetic circuits in the least shrew (Cryptotis parva). We investigated the role of 2-arachidonoylglycerol (2-AG), anandamide and methanandamide in causing emesis. 2-AG (0.25 - 10 mg/kg, i.p.) caused a dose-dependent increase in both vomiting frequency (ED50 = 1.13±1.1 mg/kg) and percent of shrews vomiting (ED50 = 0.48±3.48 mg/kg) in the 30 min observation period. Both anandamide (2.5 - 20 mg/kg) and methanandamide (5-10 mg/kg) failed to produce a dose-dependent emetic effect. The possible antiemetic action of psychoactive [Δ9-THC (1-5 mg/kg), WIN 55, 212-2 (0.25 - 5 mg/kg) and CP55, 940 (0.025 - 0.1 mg/kg)] and a nonpsychoactive cannabinoid (cann...
    Nov 14, 2001
  • Abstract
    Δ-9-THC interferes with the establishment of lithium- and amphetamine-induced place conditioning.
    The potential of Δ-9-THC to interfere with place conditioning in rats was evaluated in three experiments. Experiment 1 was designed to evaluate the potential of a low dose of THC (0.5 mg/kg, ip) to interfere with the establishment and/or the expression of lithium-induced place avoidance. Since lithium produces nausea, this experiment aimed to evaluate the potential of THC to interfere with unconditioned or conditioned nausea in rats. As measured by resistance to extinction across test trial cycles, pretreatment with THC interfered with (but did not eliminate) lithium-induced place aversion learning without producing place conditioning on its own. In Experiment 2, THC eliminated a weaker lithium-induced place aversion produced by a single conditioning trial cycle. Experiment 3 evaluated whether the interference with place aversion learning was the result of interference with nausea or interference with learning. Rats were pretreated with THC prior to place preference conditioning with amphetamine. Indeed, T...
    Nov 12, 2001
  • Abstract
    Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine 1A receptor-dependent mechanism.
    BACKGROUND AND PURPOSE: Cannabidiol has been reported to be a neuroprotectant, but the neuroprotective mechanism of cannabidiol remains unclear. We studied the neuroprotective mechanism of cannabidiol in 4-hour middle cerebral artery (MCA) occlusion mice. METHODS: Male MCA occluded mice were treated with cannabidiol, abnormal cannabidiol, anandamide, methanandamide, cannabidiol plus capsazepine, and cannabidiol plus WAY100135 before and 3 hours after MCA occlusion. The infarct size was determined after 24 hours (2,3,5-triphenyltetrazolium chloride staining). Cerebral blood flow (CBF) was measured at, before and 1, 2, 3, and 4 hours after MCA occlusion. RESULTS: Cannabidiol significantly reduced the infarct volume induced by MCA occlusion in a bell-shaped curve. Similarly, abnormal cannabidiol but not anandamide or methanandamide reduced the infarct volume. Moreover, the neuroprotective effect of cannabidiol was inhibited by WAY100135, a serotonin 5-hydroxytriptamine1A (5-HT1A) receptor antagonist but not c...
    Nov 12, 2005
  • Abstract
    δ-9-Tetrahydrocannabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in suncus murinus: an animal model of anticipatory nausea and vomiting (ANV).
    Chemotherapy patients report not only acute nausea and vomiting during the treatment itself, but also report anticipatory nausea and vomiting upon re-exposure to the cues associated with the treatment. We present a model of anticipatory nausea based on the emetic reactions of the Suncus murinus (musk shrew). Following three pairings of a novel distinctive contextual cue with the emetic effects of an injection of lithium chloride, the context acquired the potential to elicit conditioned retching in the absence of the toxin. The expression of this conditioned retching reaction was completely suppressed by pretreatment with each of the principal cannabinoids found in marijuana, δ9-tetrahydrocannabinol or cannabidiol, at a dose that did not suppress general activity. On the other hand, pretreatment with a dose of ondansetron (a 5-HT3 antagonist) that interferes with acute vomiting in this species, did not suppress the expression of conditioned retching during re-exposure to the lithium-paired context. These re...
    Nov 14, 2005
  • Abstract
    Deficits in a rodent attentional set-shifting task induced by repeated THC administration.
    Cannabis use has been associated with deficits in prefrontal- cortex dependent cognitive processes in humans. We have previously shown that acute administration of Δ9-tetrahydrocannabinol (THC) produces deficits in reversal learning (REV) and the ability to shift attention within a perceptual dimension (intradimensional shift, IDS) in an attentional set shifting task (ASST) (Egerton et al., Program No. 110.15 2003 Abstract viewer/Itinerary Planner. Washington, DC: Society for Neuroscience). However, the human literature suggests that cannabis-induced cognitive deficits are more apparent following chronic use. We therefore employed the ASST to test the hypothesis that a chronic intermittent THC treatment regime would lead to deficits in executive function that were different from those induced by acute treatment. Long Evans hooded rats were administered THC (1mg/kg i.p.) or vehicle once per week for 4 weeks and tested in the ASST 30 minutes after the last dose of THC or vehicle. Chronic intermittent THC pro...
    Oct 26, 2004
  • Abstract
    Effect of Δ9-tetrahydrocannabinol on CREB phosphorylation in rat cerebellum: An immunohistochemical study.
    Numerous CNS processes, including neurotransmitter synthesis, gene expression, and cellular proliferation are controlled by neurotransmitters acting through second messenger systems that phosphorylate the transcription factor cyclic AMP response element-binding protein (CREB). Several converging lines of evidence indicate that drug of abuse may exert their profound long-term effects on the CNS by modulating signaling pathways controlling gene expression. Cannabinoids produce locomotor effects that include hypolocomotion, ataxia and catalepsy mediated by CB1 cannabinoids receptors located in motor control regions and cognitive impairment. Since there is evidence that cerebellum have a role not only in motor function but also in cognition, the purpose of the present study was to examine the effect of the Δ9-tetrahydrocannabinol (Δ9-THC), the principal psychoactive component of marijuana, on the phosphorylation of CREB in rat cerebellum, which present an high density of cannabinoids CB1 receptors and to deter...
    Oct 26, 2004
  • CB1-Dependent Long-Term Depression in Ventral Tegmental Area GABA Neurons: A Novel Target for Marijuana | Journal of Neuroscience
    The VTA is necessary for reward behavior with dopamine cells critically involved in reward signaling. Dopamine cells in turn are innervated and regulated by neighboring inhibitory GABA cells. Using whole-cell electrophysiology in juvenile-adolescent GAD67-GFP male mice, we examined excitatory plasticity in fluorescent VTA GABA cells. A novel CB1-dependent LTD was induced in GABA cells that was dependent on metabotropic glutamate receptor 5, and cannabinoid receptor 1 (CB1). LTD was absent in CB1 knock-out mice but preserved in heterozygous littermates. Bath applied Δ9-tetrahydrocannabinol depressed GABA cell activity, therefore downstream dopamine cells will be disinhibited; and thus, this could potentially result in increased reward. Chronic injections of Δ9-tetrahydrocannabinol occluded LTD compared with vehicle injections; however, a single exposure was insufficient to do so. As synaptic modifications by drugs of abuse are often tied to addiction, these data suggest a possible mechanism for the addictiv...
    Nov 8, 2017 Lindsey Friend
  • Abstract
    SITES AND MECHANISMS OF PERIPHERAL CHEMOSENSITIVITY AFTER CAROTID (CBD) AND/OR AORTIC DENERVATION IN PIGLETS.
    Ventilatory (VE) responses to NaCN injections in the descending aorta of CBD piglets demonstrate plasticity in peripheral chemosensitivity (J.Appl.Physiol. 87:2128-2135, 1999). Further, immunostaining shows an increase in serotonin (5-HT) in the subendothelial and adventitia layers of the same aortic areas after CBD (FASEB J. 15(4):A422, 2001). The present study assesses whether the peripheral chemosensitivity after CBD in the aorta requires 5-HT and if chemosensitivity remains after combined aortic and carotid body denervation (AOD+CBD). In 25 piglets, peripheral chemosensitivity (VE responses) was assessed 3 weeks after carotid and/or aortic, or sham denervation by injections of 6.3 mM NaCN (0.05mg.kg-1) into the jugular vein, common carotid arteries and descending aorta, before (control) and after the IV administration of the 5-HT blockers, metoclopramide (MCP), and methiothepin (MTN). Venous NaCN VE responses did not differ among all groups (p = 0.531) whereas carotid responses were present in SHAM and...
    Nov 13, 2001
  • Abstract
    The effects of tetrahydrocannabinol or methylphenidate pretreatment on rat’s behavior in spatial accuracy task.
    Male rats (n = 9) were trained on the accuracy task (Kubie, et al, Abstracts, Society for Neuroscience, 2003), where rat was rewarded when visiting a target location: a 9 cm diameter unmarked circle in a cylindrical enclosure that had 2 cue-cards (black and white) separated by 90 degrees on the walls. Within 5 min sessions, rats must stand still for 1 sec in the target location in order to receive a reward. We examined the effects of tetrahydrocannabinol (THC) or methylphenidate (MPD) pretreatment on this choice response. Drugs were administered ip in increasing doses 1, 3 and 9 mg/kg/day alternating with saline and each rat received either MPD or THC. Different characteristics were registered – the number of correct choices, number of the rewards, speed and number of walking bouts during the session, median distance to choice center and goal, ratio of events in correct and false goals and others. It was found that methylphenidate slightly improved the accuracy of entering the target location since there w...
    Nov 15, 2005
  • Previous
  • 5
  • 6
  • 7
  • 8
  • 9
  • Next

Featured

  • Explore the benefits of an SfN membership
  • Upcoming Webinar: Behavioral and Evolutionary Adaptations to Changing Environments
  • Seeburg Prize nominations have been extended to February 19
SfN Websites
  • BrainFacts.org logo
  • eNeuro logo
  • JNeurosci logo
  • Neuronline logo
Engage with SfN
  • join Join
  • give Give
  • advocate Advocate
  • publish Publish
Quick Links
  • SfN News
  • For Press
  • Global Events
  • Contact Us
  • Advertise
  • Code of Conduct
  • Jobs at SfN
  • SfN Store
  • Social Media
Follow SfN
  • BlueSky logo
  • Facebook logo
  • Instagram logo
  • LinkedIn logo

  • Threads logo
  • X Logo
  • YouTube logo
SfN logo with "SfN" in a blue box next to Society for Neuroscience in red text and the SfN tag line that reads "Advancing the understanding of the brain and nervous system"
1121 14th Street NW, Suite 1010, Washington, D.C. 20005
(202) 962-4000 | 1-888-985-9246
  • Accessibility Policy
  • Disclaimer
  • Privacy Notice
  • Contact Us

Copyright ©
Society for Neuroscience